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Summary. Background: von Willebrand factor (VWF)
levels in healthy individuals are influenced by variations
in genetic loci other than the VWF gene, whose contri-
bution to VWF levels in patients with von Willebrand
disease (VWD) is largely unknown. Objectives: To inves-
tigate the association between single-nucleotide polymor-
phisms (SNPs), VWF levels, and bleeding phenotype.
Patients/Methods: In 364 type 1 VWD and 240 type 2
VWD patients from the nationwide cross-sectional
‘Willebrand in The Netherlands’ (WiN) study, we studied
the association between eight SNPs in STXBP5,
SCARA5, ABO, VWF, STAB2, STX2, TC2N, and
CLEC4M, and VWF antigen (VWF:Ag), VWF activity
(VWF:Act), and bleeding phenotype as assessed with the
Tosetto bleeding score. Results: In type 1 patients,
STXBP5 was associated with a lower VWF:Ag level
(adjusted difference of 3.0 IU dL1 per allele; 95%
confidence interval [CI] 6.0 to 0.1) and CLEC4M with
both a lower VWF:Ag level (4.3 IU dL1 per allele;
95% CI 7.9 to 0.6) and lower VWF:Act (5.7
IU dL1 per allele; 95% CI 10.9 to 0.5). In type 2
patients, none of the SNPs was associated with VWF
levels. None of the genetic variants was associated with
bleeding score. Conclusions: Genetic variations in
STXBP5 and CLEC4M are associated with VWF level
variation in type 1 VWD, but not in type 2 VWD. This
study increases our understanding of the pathophysiol-
ogy of VWD, and provides a further indication of the
involvement of STXBP5 and CLEC4M in determining
VWF levels in VWD.
Keywords: CLEC4M protein, human; polymorphism,
single nucleotide; STXBP5 protein, human; von
Willebrand disease; von Willebrand factor.
Introduction
von Willebrand disease (VWD), the commonest inherited
bleeding disorder, is caused by a reduced concentration or
aberrant activity of von Willebrand factor (VWF), and is
characterized by recurrent mucocutaneous bleeding [1,2].
Type 1 VWD is characterized by a reduced level of VWF,
and type 3 VWD by the complete absence of normal VWF,
whereas type 2 VWD patients have functionally abnormal
VWF [3].
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Even in VWD patients with identical VWF gene
mutations, VWF levels are highly variable, and the clini-
cal expression is very heterogeneous [4–6]. Studies on
the molecular pathology of type 1 VWD have shown
that mutations in the VWF gene are common in more
severe VWD cases [4,7]. However, in milder cases, the
genetic model is more complex. Incomplete penetrance
and variations in other genes probably play a greater
role [6,7].
The Cohorts for Heart and Aging Research in Geno-
mic Epidemiology (CHARGE) consortium recently dis-
covered novel genetic loci that regulate VWF antigen
(VWF:Ag) levels (Table 1) in non-VWD patients [8,9].
Two of these genes (STX2 and STXBP5) are likely to be
involved in VWF secretion by interacting with soluble N-
ethylmaleimide-sensitive factor attachment protein recep-
tor (SNARE) proteins, which have been shown to be
involved in Weibel–Palade body exocytosis [10–12]. ABO,
CLEC4M, SCARA5 and STAB2 probably play a role in
the clearance of VWF [8,13–16]. TC2N was also identi-
fied, and has since been shown to be associated with
venous thrombosis [17].
Except for the single-nucleotide polymorphism (SNP)
determining ABO blood group, which is the most impor-
tant genetic determinant of VWF:Ag levels, and the SNP
in VWF, these genes encode proteins that have not been
linked to VWF levels [15]. We have recently shown that
genetic variation in STX2 affects VWF:Ag levels in type 1
VWD patients, and Rydz et al. showed that polymor-
phisms in CLEC4M contribute to variability in VWF lev-
els [13,18]. However, it is still unknown whether these
genetic modifiers also determine the variability of VWF
levels and influence the bleeding phenotype in moderately
and severely affected type 1 and type 2 VWD patients.
Insights into these associations will increase our under-
standing of the pathophysiology of VWD, and possibly
lead to new treatment options for patients with VWD.
We therefore investigated the effects of genetic variations
in STXBP5, SCARA5, ABO, VWF, STAB2, STX2,
TC2N and CLEC4M on VWF levels and bleeding pheno-
type in a large cohort of moderately and severely affected
type 1 and type 2 VWD patients from the nationwide




This study is part of the WiN study, a nationwide cross-
sectional multicenter study among VWD patients in the
Netherlands that included 804 patients who had previ-
ously been diagnosed with type 1, type 2 or type 3 VWD
[2,19–22]. The inclusion criteria for the WiN study were:
(i) hemorrhagic diathesis or a family history of VWD;
and (ii) historically lowest levels of VWF:Ag of
≤ 30 U dL1 and/or VWF activity (VWF ristocetin cofac-
tor activity) of ≤ 30 U dL1 and/or factor VIII coagula-
tion activity of ≤ 40 U dL1 (for type 2N VWD).
Patients were excluded if they were known to have other
hemostatic disorders resulting in a hemorrhagic diathesis.
Medical Ethical Committees at all participating centers
(see Appendix) approved this study, and all participants
gave informed consent.
For the current study, only patients with type 1
(n = 364) and type 2 (n = 240) VWD for whom centrally
measured VWF levels were available were selected. Exclu-
sion criteria were pregnancy and the recent use of desmo-
pressin or replacement therapy at the time of blood
sampling.
Assessment methods
All patients completed an extensive questionnaire on
bleeding episodes and treatment of VWD [2,20–22]. To
calculate a bleeding score (BS), as previously described by
Tosetto [23], we used information on the severest lifetime
event of each of 12 specific bleeding symptoms. To avoid
prophylaxis bias, we did not score for a bleeding symp-
tom if patients had received prophylactic desmopressin or
prophylactic replacement therapy before a surgical inter-
vention, dental extraction, or delivery [2, 24]. In addition,
to gain insights into the heritability of the polymorphisms
and the VWF mutations, we obtained pedigrees from the
Table 1 Genetic loci associated with von Willebrand factor identified in the Cohorts for Heart and Aging Research in Genomic Epidemiology
consortium and analyzed in the Willebrand in The Netherlands study
Region SNP Gene Gene name (Possible) biological pathway
6q24 rs9390459 STXBP5 Syntaxin-binding protein 5 Vesicular trafficking and exocytosis
8p21 rs2726953 SCARA5 Scavenger receptor class A, member 5 Clearance
9q34 rs687621 ABO ABO blood group Clearance
12p13 rs1063857 VWF von Willebrand factor –
12q23 rs4981022 STAB2 Stabilin-2 Clearance
12q24.3 rs7978987 STX2 Syntaxin-2 Vesicular trafficking and exocytosis
14q32 rs2402074 TC2N Tandem C2 domains, nuclear Not yet known
19p13.2 rs868875 CLEC4M C-type lectin domain family 4, member M Clearance
SNP, single-nucleotide polymorphism.
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392 families that we had identified with type 1 and type 2
VWD patients.
Laboratory measurements
At inclusion in the study, venous blood was collected in
0.105 M sodium citrate tubes (1 : 10) and centrifuged
twice at 2200 9 g for 10 min at room temperature;
plasma was stored at  80 °C. Plasma levels of VWF:Ag
and VWF activity (VWF:Act) were measured centrally
(Erasmus University Medical Center, Rotterdam). VWF:
Ag levels were determined with an in-house ELISA using
polyclonal rabbit anti-human VWF antibodies and horse-
radish peroxidase-conjugated anti-human VWF antibod-
ies (DakoCytomation, Glostrup, Denmark) for detection.
VWF:Act was assessed with a LIA test, which uses mAbs
directed against the glycoprotein (GP)Iba-binding domain
of VWF and thereby reflects the binding of VWF to
GPIba (HemosIL von Willebrand Factor Activity; Instru-
mentation Laboratory, Breda, the Netherlands). Pheno-
typic blood group was determined by mixing plasma
from patients with red blood cells from donors with a
known blood group [25]. If the phenotypic blood group
was unknown, blood group was determined by genotyp-
ing the ABO blood group-specific SNPs rs687289 (marker
for blood group O), rs507666 (marker for blood
group A1), rs8176704 (marker for blood group A2), and
rs8176749 (marker for blood group B) [26]. Details of the
blood-sampling procedure and laboratory measurements
at inclusion in the study have been described in more
detail elsewhere [2].
Genotyping analysis
For DNA isolation, blood was collected in tubes contain-
ing EDTA (Beckon Dickinson, Plymouth, UK). From
this, genomic DNA was extracted according to standard
salting-out procedures [27], and stored at  20 °C. From
a subset of patients, saliva was collected in a DNA self-
collection kit (Oragene-DNA OG-250; DNA Genotek,
Ottawa, ON, Canada), and the DNA was purified with
the Puregene DNA purification kit (DNA Genotek).
Using Custom TaqMan Genotyping Assays (Applied
Biosystems, Foster City, CA, USA), we genotyped eight
SNPs that had been identified in the CHARGE consor-
tium meta-analysis (Table 1) [8]. In TC2N, rs10133762
had the highest genome-wide significance level for VWF
levels in the CHARGE consortium meta-analysis. How-
ever, because this SNP was not available in predesigned
form (Applied Biosystems), we selected polymorphism
rs2402074 in TC2N, which is in high linkage disequilib-
rium with rs10133762 (D0 = 1, R2 = 1) (International
HapMap project, phases I + II + III, August 2010; http://
www.hapmap.org and HAPLOVIEW software version 4.2
[28]). We excluded the CHARGE-identified SNP
rs17057285 (UFM1) [9] from our analyses, because of the
very low minor allele frequency (MAF) of rs17057285
(MAF = 0.005), which meant that our study would be
underpowered to assess an association between UFM1
and VWF levels.
Endpoint fluorescence was measured on the
ABI 7900HT instrument, and clustered according to
genotype with SDS 2.1 software (both Applied Biosys-
tems). To ensure DNA quality, we included only patients
in whom genotyping had been successful for > 75% of
SNPs.
Statistical methods
Descriptive statistics for categorical data are presented as
frequencies and percentages (n, %), and those for contin-
uous variables as median and 25–75% interquartile range
(IQR). As VWF:Ag and VWF:Act levels were skewed,
these data were quadratically transformed (square root)
for the regression analysis. As the regression results for
non-transformed and transformed data were similar, we
describe the untransformed data, as they are more easily
interpreted. As an appropriate transformation for BS,
which was skewed to the right, was not found, we used
Kruskal–Wallis tests to test the statistical significance of
differences in BS between genotypes. As type 1 and
type 2 VWD have different pathophysiologies, all analy-
ses were stratified for type of VWD.
Allele frequencies were calculated by genotype count-
ing. For each SNP, the deviation from Hardy–Weinberg
equilibrium was tested by means of a chi-squared test
with one degree of freedom. To compare MAFs between
CHARGE and WiN, the chi-squared test was used.
We performed linear regression analysis with additive
genetic models to quantify differences in VWF:Ag or
VWF:Act levels between patients with different geno-
types, using the genotype of each SNP as a continuous
variable. All models were adjusted for age, sex, and blood
group, except for the SNP in ABO (rs687621), which was
only adjusted for age and sex (model 1). In model 2, we
also adjusted for pedigree structure with SOLAR, ver-
sion 6.6.2 (Texas Biomedical Research Institute, San
Antonio, TX, USA). Beta-coefficients (b) are interpreted
as a reduction in VWF:Ag or VWF:Act levels per VWF-
reducing allele with a 95% confidence interval (CI).
We also calculated each individual’s total number of
VWF-reducing alleles of the SNPs that were associated
with VWF:Ag levels (rs9390459 in STXBP5 and rs868875
in CLEC4M) (maximum of 4). The Kruskal–Wallis test
was used to test differences in VWF:Ag and VWF:Act
between numbers of STXBP5 and CLEC4M VWF-reduc-
ing alleles in type 1 and type 2 VWD. The Mann–Whit-
ney U-test was used to test the statistical significance of
differences between numbers of STXBP5 and CLEC4M
VWF-reducing alleles. We performed linear regression
analysis to quantify the differences in VWF:Ag or VWF:
Act between patients with different numbers of STXBP5
© 2015 International Society on Thrombosis and Haemostasis
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and CLEC4M VWF-reducing alleles. Statistical analyses
were performed with SPSS for Windows, version 21.0
(SPSS, Chicago, IL, USA). A P-value of < 0.05 was con-
sidered to be statistically significant. With the Bonferroni
correction method for multiple testing, the significance
level was set at 0.006 (0.05/8).
Results
Participants
A total of 804 VWD patients participated in the WiN
study; DNA was obtained from 752 of them. The follow-
ing patients were excluded from the present analyses: all
type 3 VWD patients (n = 43); patients without centrally
measured VWF levels (n = 76); pregnant patients (n = 8);
patients who used desmopressin or clotting factor concen-
trate < 72 h before blood sampling (n = 10); and patients
in whom the success rate of genotyping was < 75%
(n = 11). Therefore, a total of 604 VWD patients were
included, 364 of whom had type 1 VWD and 240 of
whom had type 2 VWD (Fig. 1). BS was available for
350 type 1 patients and 224 type 2 patients. The baseline
characteristics are shown in Table 2.
MAFs in VWD patients relative to the general population
Table 3 shows the MAFs of the SNPs in VWD patients.
Among type 1 VWD patients, the MAF of rs687621
(ABO) was 19%, which is lower than that previously
reported (34%) in white Caucasian subjects (CHARGE
consortium) [8] and in the Dutch population [29]
(P < 0.001). This reflects the higher prevalence of blood
group O in our study population, as this SNP reflects the
O allele. The MAF of rs1063857 (in VWF), the minor
allele being the one associated with higher VWF:Ag lev-
els, was decreased among type 1 VWD patients (24% ver-
sus 36% in CHARGE, P < 0.001) and type 2 VWD
patients (24% versus 36% in CHARGE, P < 0.001). In
addition, the MAF of rs4981022 (STAB2), the frequency
of the allele associated with lower VWF:Ag levels, was
slightly increased among type 1 VWD patients; 35%






Centrally measured VWF and FVIII levels unavailable
N = 76
VWD patients pregnant at time of blood sampling
N = 8
N = 10
Use of desmopressin or replacement therapy <  72 h before blood sampling
Success rate of






Type 1 VWD N = 364
Type 3 VWD patients
Type 2 VWD N = 240
Type 1 VWD N = 350
Bleeding score available
Type 2 VWD N = 224
Fig. 1. Flowchart of included patients. SNP, single-nucleotide polymorphism; VWD, von Willebrand disease; VWF, von Willebrand factor;
WiN, Willebrand in The Netherlands study.
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versus 32% in CHARGE (P = 0.054). The MAF of
rs9390459 (STXBP5) was lower in type 2 VWD patients
than previously reported in CHARGE; 39% versus 44%
(P = 0.026). The MAFs of the other SNPs did not differ
between VWD patients and CHARGE subjects.
Association between genetic variations and VWF parameters
In type 1 VWD patients, rs868875 in CLEC4M was asso-
ciated with lower VWF:Ag levels (adjusted difference of
–4.3 IU dL1 per allele; 95% CI 7.9 to 0.6), and
rs9390459 in STXBP5 was borderline associated with
lower VWF:Ag levels (3.0 IU dL1 per allele; 95%
CI 6.0 to 0.1) (Fig. 2; Table 4: model 1). After addi-
tional adjustment for pedigree (model 2), a similar but
not significant trend was observed for these two SNPs in
CLEC4M and STXBP5 (for CLEC4M, adjusted differ-
ence of 3.3 IU dL1 per allele [95% CI 6.8 to 0.2];
and for STXBP5, 2.6 IU dL1 per allele [95% CI 5.5
to 0.4]). In addition, after adjustment for multiple testing
with the Bonferroni method, the difference lost its statisti-
cal significance. The contributions of CLEC4M and
STXBP5 to VWF:Ag levels in a subgroup of type 1
VWD patients with VWF:Ag levels of > 20 IU dL1 were
larger, with 5.1 IU dL1 per allele (95% CI 8.7 to
1.5) for CLEC4M, and 4.2 IU dL1 per allele (95%
CI 7.3 to 1.2) for STXBP5, and remained significant
after Bonferroni correction. All associations were similar
for VWF:Act (Fig. 2; Table 4). In type 1 VWD patients,
the remaining SNPs were not associated with VWF:Ag or
VWF:Act. In type 2 VWD, rs1063857 in VWF was
associated with lower VWF:Act levels (adjusted difference
of 5.1 IU dL1 per allele; 95% CI 9.0 to 1.2),
but not with VWF:Ag. None of the other SNPs was
associated with VWF:Ag or VWF:Act levels (Table 4).
Numbers of STXBP5 and CLEC4M VWF-reducing alleles and
VWF levels
Among patients with type 1 VWD, an increasing number
of VWF-reducing alleles of STXBP5 or CLEC4M was
associated with increasingly lower VWF:Ag and VWF:
Act levels. VWF:Ag levels were reduced by 3.5 IU dL1
(95% CI 1.3 to 5.8) per allele of STXBP5 or CLEC4M,
and VWF:Act levels were reduced by 4.7 IU dL1
(95% CI 1.5 to 8.0) per allele (adjusted for age, sex, and
blood group). Type 1 patients with two VWF-reducing
alleles of STXBP5 or CLEC4M had the lowest VWF:Ag
levels (median VWF:Ag level of 34 IU dL1; IQR 21–47)
(Fig. 3).
Among type 2 VWD patients, numbers of STXBP5
and CLEC4M VWF-reducing alleles were not associated
with VWF:Ag or VWF:Act (for VWF:Ag, adjusted differ-
ence of 1.4 IU dL1 [95% CI 0.9 to 3.6]; and for VWF:
Act, 0.3 IU dL1 [95% CI 2.9 to 2.2]) (Fig. 3).
Association between genetic variations and bleeding
phenotype
Among type 1 VWD patients, homozygous carriers for
the VWF-reducing alleles of ABO had a slightly higher
BS: CC (n = 15), median BS of 6.0 (IQR 2.0–9.0); CT
(n = 102), median BS of 8.5 (IQR 5.0–14.3); and TT
(n = 232), median BS of 9.0 (IQR 5.0–15.0) (P for
trend = 0.072). Median BS did not differ between the
Table 3 Minor allele frequencies (MAFs)
SNP Gene CHARGE Type 1 VWD (95% CI) Type 2 VWD (95% CI)
rs9390459 STXBP5 0.44 0.47 (0.44 to 0.51) 0.39† (0.35 to 0.44)
rs2726953 SCARA5 0.31 0.29 (0.26 to 0.33) 0.29 (0.24 to 0.33)
rs687621 ABO 0.34 0.19* (0.17 to 0.22) 0.31 (0.27 to 0.35)
rs1063857 VWF 0.36 0.24* (0.21 to 0.27) 0.24* (0.21 to 0.28)
rs4981022 STAB2 0.32 0.35 (0.31 to 0.39) 0.32 (0.28 to 0.36)
rs7978987 STX2 0.35 0.33 (0.30 to 0.37) 0.37 (0.32 to 0.41)
rs2402074 TC2N 0.44 0.43 (0.40 to 0.47) 0.43 (0.38 to 0.47)
rs868875 CLEC4M 0.26 0.29 (0.26 to 0.32) 0.29 (0.25 to 0.34)
CHARGE, the previously reported minor allele frequency in healthy individuals in the Cohorts for Heart and Aging Research in Genomic Epi-
demiology study [8]; CI, confidence interval; SNP, single-nucleotide polymorphism; VWD, von Willebrand disease. *P < 0.001. †P = 0.025.






Age (years), median (range) 45 (1–81) 43 (3–83)
Child (0–16 years), n (%) 33 (9) 22 (9)
Male sex, n (%) 121 (33) 107 (45)
VWD subtype 2, n (%)
2A – 155 (65)
2B – 45 (19)
2M – 26 (11)
2N – 14 (6)
Blood group O, n (%) 245 (67) 120 (50)
VWF:Ag (IU dL1), median (IQR) 37 (23–53) 25 (16–34)
VWF:Act (IU dL1), median (IQR) 45 (24–70) 9 (4–16)
Bleeding score, median (IQR) 9 (5–14.3) 12 (8–17)
IQR, interquartile range; VWD, von Willebrand disease; VWF:Act,
von Willebrand factor activity; VWF:Ag, von Willebrand factor anti-
gen. VWF:Ag and VWF:Act levels were measured centrally at time
of inclusion in the study.
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genotypes of STAB2 (P = 0.531), STXBP5 (P = 0.484),
SCARA5 (P = 0.904), VWF (P = 0.628), CLEC4M
(P = 0.273), TC2N (P = 0.362), and STX2 (P = 0.743).
None of the SNPs was associated with BS in type 2
VWD patients.
Discussion
In this cohort of moderately and severely affected VWD
patients from the WiN study, we observed that genetic
variations in CLEC4M and STXBP5 contribute to the
variability in VWF:Ag and VWF:Act levels in type 1
VWD, but not in type 2 VWD. Bleeding phenotype
appeared not to be associated with variations in these
genetic loci outside the VWF gene that have been shown
to contribute to variability in VWF levels.
It is well known that VWF levels are highly variable in
VWD patients [4,5,7]. Besides mutations or polymorphisms
in VWF, genetic variations in other genes may also affect
VWF levels [6,7]. We have now found that this variability
in VWF levels in VWD patients is partly explained by
polymorphisms in CLEC4M and STXBP5. The effect sizes
that we found for these SNPs were similar to those
observed by the CHARGE consortium [8]. It should be
noted that, after correction for multiple testing, this
finding lost its significance, but this might also have intro-
duced a type 2 error. It remained significant for VWD
type 1 patients with VWF:Ag levels of > 20 IU dL1, who
are known to have VWF mutations less frequently than
type 1 patients with VWF:Ag levels of < 20 IU dL1 or
type 2 VWD patients. VWF has previously been shown to
undergo receptor-mediated endocytosis after binding to the
CLEC4M receptor [13]. It is probably involved in VWF
clearance, which is a mechanism leading to lower VWF lev-
els in VWD patients. STXBP5 interacts with SNARE pro-
teins, which drive vesicle exocytosis through the fusion of
granules and target membranes [10]. These SNARE pro-
teins have been shown to be involved in Weibel–Palade
Body exocytosis, a well-known mechanism for VWF
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Fig. 2. von Willebrand factor antigen (VWF:Ag) and von Willebrand factor activity (VWF:Act) level per genotype of (A) rs9390459 in
STXBP5 and (B) rs868875 in CLEC4M in type 1 von Willebrand disease patients. The boxplots indicate the median, 25–75% interquartile
range, and 1–99 percentile.
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likely to lead to VWD. This is further supported by the
recent observation that a STXBP1 mutation lowers VWF:
Ag levels and reduces VWF secretion from the endothe-
lium. This mutation was identified in an early infantile epi-
leptic encephalopathy type 4 patient, and the protein
STXBP1 is also a member of the SNARE family [30]. By
combining the numbers of VWF-reducing alleles of
STXBP5 and CLEC4M, we found a strong association
between VWF levels and these numbers of VWF-reducing
alleles. This indicates that these two genes have an additive
effect on VWF levels in type 1 VWD patients, and that car-
riage of both results in even lower VWF levels.
It is common knowledge that ABO blood group influ-
ences VWF levels [31]. ABO was also shown within the
CHARGE consortium to be the major genetic determinant
of VWF:Ag levels, with an effect size of 24.1% per VWF-
reducing allele. However, in our cohort of VWD patients,
blood group O was not associated with lower VWF levels.
This is explained by a phenomenon called index event bias
[32]. The WiN cohort comprised patients with VWF levels
lower than 30%, resulting in an overrepresentation of
blood group O in our cohort of type 1 VWD patients.
Patients with non-O blood groups have different causes for
having low VWF levels. These other causes explain why
patients with non-O blood groups have similar VWF levels
as patients with blood group O in our study. The index
event bias may also play a role in the VWF SNP. It is of
importance that we observed lower frequencies of the ABO
SNP and the VWF SNP that are associated with increased
levels of VWF in our type 1 VWD group as compared with
those observed in healthy individuals in CHARGE. This
indicates that these genetic variations, by influencing VWF
levels, may also determine whether an individual is diag-
nosed as a moderately or severely affected VWD patient
(levels of < 30 IU dL1) and therefore be included in the
WiN study.
In 2012, we were the first to report that genetic varia-
tion in STX2, which encodes a binding substrate for
STXBP5 [10], was associated with VWF:Ag levels in
type 1 VWD patients [18]. Our current study found no
such association. This may have been because in our pre-
vious study the lowest VWF levels ever measured were
used for analyses, and for our current analysis we used
VWF parameters measured centrally at inclusion in the
study. We now have a larger sample size, and we adjusted
not only for blood group – which has been shown to
determine 25% of the VWF levels – but also for pedi-
grees. Of the 364 type 1 VWD patients from the current
study, 131 (36%) were included in both analyses.
In most of the type 2 VWD patients and in the major-
ity of the type 1 VWD patients, mutations in VWF can
be detected. The fact that molecular studies have been
unable to find causative VWF gene mutations in 35% of
type 1 VWD patients, especially in those with levels
above 20 IU dL1, suggests that other genetic loci con-
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genes is more likely in the mildly affected patients, in
which the genetic model is more complex [6,7]. This is
also observed in our study, because, in mildly affected
VWD patients, the contribution of polymorphisms in
STXBP5 and CLEC4M to VWF levels is even larger.
Our study supports the concept of the involvement of
STXBP5 and CLEC4M in determining the variability of
VWF levels, not only in healthy individuals, but also in
type 1 VWD patients.
In type 2 VWD patients, we found no association
between these genetic loci and VWF levels, probably
because of the different pathophysiology of this type of
VWD. Because the reduced VWF levels in these type 2
VWD patients mainly result from a specific mutation in
VWF that causes a functionally aberrant VWF protein to
be produced, the additional effect of genetic variations on
VWF levels may be extremely small. Unfortunately, the
number of type 2 VWD types in our cohort was relatively
low, so we may not have had enough power to establish
an association between genetic variations and VWF levels
in type 2 VWD and its different subtypes.
If genetic loci outside VWF contribute to the variability
of VWF levels in VWD patients, it may be expected that
they will affect the bleeding phenotype in these patients,
as VWF levels and bleeding phenotype are associated
[2,23,33]. In our cohort, however, we found no associa-
tion between these genetic loci and bleeding phenotype,
as determined with the Tosetto BS [23]. The known limi-
tations of the Tosetto BS (cumulative score, ceiling effect,
and prophylaxis bias), possible selection bias or the rela-
tively small influence of the genetic variants on VWF lev-
els may explain the lack of association between bleeding
phenotype and genetic variations [2,23,24]. However, this
BS is the best currently available method for evaluating
bleeding phenotype in VWD.
The strength of our study is that it is the first to exam-
ine the relationship between genetic variations in
STXBP5, SCARA5, ABO, STAB2, STX2, TC2N and
CLEC4M in patients with moderate or severe type 1 and
type 2 VWD. Another very important strength is our use
of pedigrees from all patients in the association analysis.
In addition, our population covered almost all of the
patients with moderate or severe VWD in the Nether-
lands, and centrally measured VWF and FVIII levels
were available from all included patients. A study limita-
tion is that VWF mutation analysis has not yet been per-
formed in all patients. To compensate for this, we
used pedigrees to adjust for the effect size of large fami-
lies on VWF levels, and to avoid bias resulting from
polymorphisms that may be in high linkage with the
Type 1 VWD Type 2 VWD
VWF : Ag : P for trend = 0.002 VWF : Ag : P for trend = 0.224







































































n = 51 n = 128 n = 120 n = 55 n = 36 n = 104 n = 70 n = 26
No. of VWF-reducing alleles of STXBP5 and CLEC4MNo. of VWF-reducing alleles of STXBP5 and CLEC4M
2 ≥ 3 0 1 2 ≥ 3
A B
Fig. 3. Numbers of von Willebrand factor (VWF)-reducing alleles of STXBP5 and CLEC4M in type 1 and type 2 von Willebrand disease
(VWD), and VWF antigen (VWF:Ag) and VWF activity (VWF:Act) levels per number of VWF-reducing alleles of STXBP5 and CLEC4M in
(A) type 1 and (B) type 2 VWD. The boxplots indicate the median, 25–75% interquartile range (IQR), and extreme values. In type 1 VWD
patients with no, one, two or three or more VWF-reducing alleles of STXBP5 and CLEC4M, the median VWF:Ag levels were: 42 IU dL1
(IQR 20–62), 40 IU dL1 (IQR 26–60), 34 IU dL1 (IQR 21–47), and 34 IU dL1 (IQR 27–47), respectively, and the median VWF:Act levels
were 51 IU dL1 (IQR 21–75), 51 IU dL1 (IQR 30–80), 39 IU dL1 (IQR 21–63), and 39 IU dL1 (IQR 24–60), respectively. In type 2
VWD patients with no VWF-reducing alleles of STXBP5 and CLEC4M, the median VWF:Ag level was 20 IU dL1 (IQR 12–29) and the med-
ian VWF:Act level was 6 IU dL1 (IQR 3–14). In type 2 VWD patients with one VWF-reducing allele of STXBP5 and CLEC4M, the median
VWF:Ag and VWF:Act levels were 25 IU dL1 (IQR 8–33) and 8 IU dL1 (IQR 5–17), respectively. In type 2 VWD patients with two VWF-
reducing alleles of STXBP5 and CLEC4M, the median VWF:Ag and VWF:Act levels were 25 IU dL1 (IQR 16–36) and 11 IU dL–1
(IQR 5–16), respectively. In type 2 VWD patients with more than three VWF-reducing alleles of STXBP5 and CLEC4M, the median VWF:Ag
and VWF:Act levels were 25 IU dL1 (IQR 16–35) and 11 IU dL1 (IQR 4–15), respectively.
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mutation in VWF. Also, even though this is the largest
cohort study of type 1 and type 2 VWD patients in
whom associations between genetic variations and VWF
levels and bleeding phenotype have been analyzed, the
size of the study population is still relatively small for a
genetic association study, and the findings should be
interpreted with care.
In conclusion, VWF level variation in type 1 VWD is
influenced by genetic variation in CLEC4M and
STXBP5. In type 2 VWD, no associations were found
between genetic loci outside VWF and VWF level varia-
tion. Although genetic variants modestly affected VWF
levels, they were not associated with bleeding phenotype.
By increasing our understanding of the pathophysiologic
mechanisms of VWD, this study may contribute to the
search for novel causes and new therapeutic options for
this bleeding disorder.
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